SG11201403272YA - Compositions and methods for treating alzheimer's disease - Google Patents
Compositions and methods for treating alzheimer's diseaseInfo
- Publication number
- SG11201403272YA SG11201403272YA SG11201403272YA SG11201403272YA SG11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA SG 11201403272Y A SG11201403272Y A SG 11201403272YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- compositions
- methods
- treating alzheimer
- alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558430P | 2011-11-10 | 2011-11-10 | |
| US201261589809P | 2012-01-23 | 2012-01-23 | |
| US201213582308A | 2012-08-31 | 2012-08-31 | |
| PCT/US2012/064722 WO2013071267A1 (fr) | 2011-11-10 | 2012-11-12 | Compositions et méthodes de traitement de la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201403272YA true SG11201403272YA (en) | 2014-08-28 |
Family
ID=48290671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403272YA SG11201403272YA (en) | 2011-11-10 | 2012-11-12 | Compositions and methods for treating alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2780082A4 (fr) |
| CN (1) | CN104093454A (fr) |
| AU (1) | AU2012335014A1 (fr) |
| CA (1) | CA2855669A1 (fr) |
| EA (1) | EA201491851A1 (fr) |
| HK (1) | HK1201771A1 (fr) |
| SG (1) | SG11201403272YA (fr) |
| WO (1) | WO2013071267A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2644335C2 (ru) | 2010-03-03 | 2018-02-08 | Зе Юниверсити Оф Бритиш Коламбия | Эпитоп, специфичный к олигомеру амилоида бета, и антитела |
| EP3102611A4 (fr) * | 2014-02-03 | 2017-08-23 | Cangene Corporation | Molécules de liaison à des bêta-amyloïdes humanisées et utilisations de celles-ci |
| WO2016008047A1 (fr) * | 2014-07-14 | 2016-01-21 | Cangene Corporation | Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde |
| WO2016187339A1 (fr) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | Clairance de galantamine d'amyloides |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| EP3374380A4 (fr) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | Épitopes en c-terminal dans la bêta-amyloïde et anticorps conformationnels sélectifs associés |
| US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| CA3004496A1 (fr) * | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Epitopes dans la beta-amyloide et anticorps conformationnels selectifs associes |
| CA3004494A1 (fr) * | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes dans la region centrale de la beta-amyloide et anticorps conformationnels selectifs associes |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| CN112661828B (zh) * | 2021-01-15 | 2022-04-01 | 武汉大学 | 一种突触素的抗原肽及其抗体与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9045555B2 (en) * | 2008-07-01 | 2015-06-02 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccine against amyloid folding intermediate |
| US20110306605A1 (en) * | 2008-12-22 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Coumarin-based compounds for the treatment of alzheimer's disease and cancer |
| KR20130043088A (ko) * | 2010-02-09 | 2013-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 면역검정 표준물 및 검정내 보정 표준물을 사용한 임상 바이오마커의 측정 |
| RU2644335C2 (ru) * | 2010-03-03 | 2018-02-08 | Зе Юниверсити Оф Бритиш Коламбия | Эпитоп, специфичный к олигомеру амилоида бета, и антитела |
| WO2016008047A1 (fr) * | 2014-07-14 | 2016-01-21 | Cangene Corporation | Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde |
-
2012
- 2012-11-12 CN CN201280066632.7A patent/CN104093454A/zh active Pending
- 2012-11-12 WO PCT/US2012/064722 patent/WO2013071267A1/fr not_active Ceased
- 2012-11-12 AU AU2012335014A patent/AU2012335014A1/en not_active Abandoned
- 2012-11-12 CA CA2855669A patent/CA2855669A1/fr not_active Abandoned
- 2012-11-12 SG SG11201403272YA patent/SG11201403272YA/en unknown
- 2012-11-12 HK HK15102253.1A patent/HK1201771A1/xx unknown
- 2012-11-12 EP EP12847618.1A patent/EP2780082A4/fr not_active Withdrawn
- 2012-11-12 EA EA201491851A patent/EA201491851A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2855669A1 (fr) | 2013-05-16 |
| EP2780082A1 (fr) | 2014-09-24 |
| WO2013071267A1 (fr) | 2013-05-16 |
| CN104093454A (zh) | 2014-10-08 |
| AU2012335014A1 (en) | 2014-06-19 |
| HK1201771A1 (en) | 2015-09-11 |
| EP2780082A4 (fr) | 2015-08-05 |
| EA201491851A1 (ru) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2707369A4 (fr) | Compositions et procédés pour traiter la maladie d'alzheimer | |
| SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
| ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
| SMT201800678T1 (it) | Composizioni farmaceutiche per il trattamento del morbo di alzheimer | |
| IL236054A0 (en) | Compositions and methods for treating Crohn's disease and related conditions and infections | |
| EP2655334A4 (fr) | Compositions et méthodes utilisables en vue du traitement de maladies | |
| IL229257A0 (en) | Preparations and methods for the treatment of diseases related to the retina of the eye | |
| EP2621588A4 (fr) | Procédés et compositions pour le traitement de maladie en utilisant l'inhalation | |
| ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| ZA201404676B (en) | Compositions and methods for treating metabolic disorders | |
| ZA201404187B (en) | Compositions and methods for treating dental conditions | |
| IL231158A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| IL231157A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| EP2485733A4 (fr) | Procédés pour le traitement de la maladie d'alzheimer | |
| EP2766728A4 (fr) | Compositions et méthodes de traitement et de prévention d'une coronaropathie | |
| SMT201800249T1 (it) | Composizioni e metodi per trattare la malattia celiaca | |
| GB2496801B (en) | A method of treating alzheimer's disease | |
| IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
| IL217149A0 (en) | Compositions and methods for treating parkinson's disease | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| ZA201207226B (en) | Compositions and methods for treating viral diseases | |
| SG11201402899TA (en) | Methods and compositions for treating viral diseases | |
| HK1195902A (en) | Compositions and methods for treating alzheimer's disease | |
| PL2593129T3 (pl) | Nonapeptyd pat do stosowania w leczeniu choroby alzheimera |